# A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

> **NCT05709093** · PHASE3 · TERMINATED · sponsor: **TJ Biopharma Co., Ltd.** · enrollment: 10 (actual)

## Conditions studied

- Myelodysplastic Syndromes(MDS)

## Interventions

- **DRUG:** Lemzoparlimab+Azacitidine (AZA)
- **DRUG:** Azacitidine (AZA)

## Key facts

- **NCT ID:** NCT05709093
- **Lead sponsor:** TJ Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-03-30
- **Primary completion:** 2024-04-01
- **Final completion:** 2024-04-01
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Company Development strategy adjustment\]
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05709093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05709093, "A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05709093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*